High-throughput screening SRU Biosystems specializes in high-throughput, label-free sensing technologies (BIND) for rapid screening of cell-based and biochemical interactions, presenting a scalable platform for drug discovery, target validation, and genomics/proteomics research collaborations.

Platform diversification Technology is integrated across microtiter plates, microarray slides, and microfluidic formats, offering multiple deployment options for potential customers in pharma, diagnostics, and academic labs seeking adaptable screening tools.

Emerging customer base With a small to mid-sized team and annual revenue in the low to mid single digits, SRU presents a growth opportunity for strategic partnerships, ARR acceleration, and co-development deals with larger biotechs seeking novel screening capabilities.

Competitive positioning Compared to peers like Carterra and Axion BioSystems, SRU can leverage niche high-sensitivity, label-free screening advantages to target customers needing rapid, low-volume screening and customization for specialized targets.

Market expansion potential The BIND platform supports applications across genomics, proteomics, diagnostics, and pharmaceutical screening, indicating cross-market upsell opportunities into clinical labs, contract research organizations, and academic translational science programs.